Biotech & Medtech
Biotech & Medtech news — Friday 20 November 2026
22 stories from 4 sources, every one in English. Each links to its publisher.
-
STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
The Food and Drug Administration said Friday that it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics. The decision to block the treatment, called deramiocel, from…
-
Digital Platforms Give Consumers a Map to Navigate New Ways to Access Medicines
Direct-to-consumer platforms for prescription medicines are growing, but patients need support to use them as part of a broader journey through the healthcare system. Such platforms were the topic of a recent panel discussion at MedCity…
-
ICE detention of Princeton scientist rattles academia
A graduate student who is a scientific researcher at Princeton University was detained by Immigration and Customs Enforcement earlier this week while traveling home after presenting research at the annual Society for Neuroscience…
-
15 Organizations Call on Congress to Address Abuse of Drug Patent System
Fifteen consumer advocacy groups urged Congress to reform drug patent laws, arguing pharmaceutical companies exploit them to delay competition and raise prices. The post 15 Organizations Call on Congress to Address Abuse of Drug Patent…
-
STAT+: Is MAHA’s think tank in the tank? Tax filings show low reserves
WASHINGTON —The MAHA Institute, a nonprofit “think tank” launched to support Robert F. Kennedy Jr.’s health agenda, burned over $1 million in 2025, leaving it with little cash on hand to continue operating, tax documents obtained by STAT…
-
Will the first approved psychedelic become a blockbuster?
Compass and Usona are vying for an FDA first, but pricing, payer coverage and patient access could determine the commercial winner.
-
STAT+: Medicare pilot will test ‘food is medicine’ and other lifestyle programs to counter chronic diseases
WASHINGTON — Department of Health and Human Services officials announced Friday that 15 groups around the U.S. will test how well nutrition, exercise, and other lifestyle programs work to improve Medicare patients’ health and save the…
-
Erasca data add to pressure facing Revolution’s breakthrough cancer drug
Rasonque is already off to one of the best oncology launches in history. But certain limitations leave an opportunity that companies like Erasca — which is nearing the start of a Phase 3 trial — may be able to exploit.
-
STAT+: Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them . Don’t be shy…
-
What HEDIS Can’t See in an Asthma Follow-Up Visit
This opportunity that HEDIS has created for patients who were too often discharged and forgotten is well past due — but it’s up to clinicians to take it a step further to figure out why each patient lost control. The post What HEDIS Can’t…
-
STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to catch up on our reading…
-
STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today’s newsletter has a bit of everything: peptides, China, Congress, and cancer drugs. Biotech in 2026 is never…
-
Researchers explore possibility of a CTE blood test
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Good morning, everyone. Are you a fan of “Grand Theft Auto”? Will your boss not give you the day off to play the video game…
-
Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
Wall Street analysts rushed to Celldex’s defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva’s research chief accepted a new job.
-
This week in charts: Biotech investors’ China bets are already paying off
This year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.
-
FDA’s search for a new leader, and China’s largest drugmakers
On this week’s episode of “The Readout LOUD”: The FDA is once again searching for a new leader, a closely tracked lung cancer drug suffers an FDA rejection, and China’s largest drugmakers ranked. We invite you to listen to this…
-
Patients have little say in how brain implant trials are done. Ian Burkhart wants to change that
So you’ve been diagnosed with ALS — what now? Maybe you join a clinical trial for a brain implant that could help you do things like move your hand or talk to your loved ones. But can you influence the research as a participant? And what…
-
Opinion: More surgeons in Africa isn’t enough when only 10% are women
A voice cuts through the commotion of the Kigali operating room — calm and resolute, directing the staff as they prep the patient. Standing at the head of the table is Dr. Françoise Mukagaju, the first female plastic surgeon in Rwanda…
-
Opinion: More doctors should prescribe exercise after a concussion
Two decades ago, a Vespa accident put me in a coma. By the time I came home from acute rehab, I had lost 25 pounds, most of it muscle, and my left side did not work as it should. After months of hospital sponge baths, soaking in a warm…
-
STAT+: UnitedHealth sues to reverse downgraded Medicare Advantage quality scores
UnitedHealth Group has sued the federal government over its lowered Medicare Advantage star ratings for next year, further plunging the program’s ratings system into disarray. UnitedHealth marks at least the 15th Medicare Advantage plan to…
-
A Matter of Representation: Evolving Partial Spreads for Bent Functions
arXiv:2611.26011v1 Announce Type: new Abstract: Partial spread ($\mathcal{PS}$) bent functions are Boolean functions of maximum nonlinearity built from families of subspaces that pairwise intersect only in the null vector. We design an…
-
STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China
A few of the largest pharmaceutical companies have told a Congressional committee that they do not plan to start new clinical trial sites in the Xinjiang region of China or at hospitals affiliated with the Chinese military. The disclosure…